(2-Aminopyrimidin-5-yl)boronic acid → 5-(9-methyl-6-morpholino-9H-purin-2-yl)pyrimidin-2-amine
Reaktionsgleichung
Cl[C:2]1[N:10]=[C:9]2[C:5]([N:6]=[CH:7][N:8]2[CH3:11])=[C:4]([N:12]2[CH2:17][CH2:16][O:15][CH2:14][CH2:13]2)[N:3]=1.[NH2:18][C:19]1[N:24]=[CH:23][C:22](B(O)O)=[CH:21][N:20]=1>>[CH3:11][N:8]1[CH:7]=[N:6][C:5]2[C:9]1=[N:10][C:2]([C:22]1[CH:21]=[N:20][C:19]([NH2:18])=[N:24][CH:23]=1)=[N:3][C:4]=2[N:12]1[CH2:17][CH2:16][O:15][CH2:14][CH2:13]1Komponenten
3
Versuchsvorschrift
4-(2-Chloro-9-methyl-9H-purin-6-yl)morpholine (95 mg) was reacted with 2-aminopyrimidine-5-boronic acid, pinacol ester via General Procedure A and purified via reverse phase HPLC to give 26.1 mg of 127 as a white solid. MS (Q1) 313.2 (M)+
Aufarbeitung
- custompurified via reverse phase HPLC
Quellen und Nachweise
- ORD-Eintrag
- ord-5ddf4a9ef91b4b4ababdc2b4929477b1